DK1881850T3 - GLP-1-PEGylerede forbindelser - Google Patents

GLP-1-PEGylerede forbindelser

Info

Publication number
DK1881850T3
DK1881850T3 DK06759598.3T DK06759598T DK1881850T3 DK 1881850 T3 DK1881850 T3 DK 1881850T3 DK 06759598 T DK06759598 T DK 06759598T DK 1881850 T3 DK1881850 T3 DK 1881850T3
Authority
DK
Denmark
Prior art keywords
glp
compounds
decreasing
intestinal
gastric
Prior art date
Application number
DK06759598.3T
Other languages
English (en)
Inventor
Rohn Lee Junior Millican
Lianshan Zhang
Andrew Mark Vick
John Philip Mayer
Wolfgang Glaesner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1881850T3 publication Critical patent/DK1881850T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK06759598.3T 2005-05-13 2006-05-11 GLP-1-PEGylerede forbindelser DK1881850T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68068805P 2005-05-13 2005-05-13
PCT/US2006/018284 WO2006124529A1 (en) 2005-05-13 2006-05-11 Glp-1 pegylated compounds

Publications (1)

Publication Number Publication Date
DK1881850T3 true DK1881850T3 (da) 2011-01-03

Family

ID=36926842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06759598.3T DK1881850T3 (da) 2005-05-13 2006-05-11 GLP-1-PEGylerede forbindelser

Country Status (25)

Country Link
US (1) US8183340B2 (da)
EP (1) EP1881850B1 (da)
JP (2) JP5225074B2 (da)
KR (1) KR101011081B1 (da)
CN (1) CN101166545B (da)
AT (1) ATE482724T1 (da)
AU (1) AU2006247734B2 (da)
BR (1) BRPI0609676A2 (da)
CA (1) CA2608311C (da)
CY (1) CY1110853T1 (da)
DE (1) DE602006017202D1 (da)
DK (1) DK1881850T3 (da)
EA (1) EA012442B1 (da)
ES (1) ES2350852T3 (da)
HR (1) HRP20100543T1 (da)
IL (1) IL186772A0 (da)
ME (1) ME02786B (da)
MX (1) MX2007014052A (da)
NO (1) NO20076415L (da)
PL (1) PL1881850T3 (da)
PT (1) PT1881850E (da)
RS (1) RS51637B (da)
SI (1) SI1881850T1 (da)
UA (1) UA90896C2 (da)
WO (1) WO2006124529A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095456A1 (en) 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
EP2164519A2 (en) * 2007-06-08 2010-03-24 Ascendis Pharma AS Long-acting polymeric prodrugs of exendin
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2009075788A1 (en) * 2007-12-05 2009-06-18 Semprus Biociences Corporation Synthetic non-fouling amino acids
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
IT1392655B1 (it) * 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
DK2470552T3 (da) 2009-08-26 2014-02-17 Sanofi Sa Hidtil ukendte, krystallinske, heteroaromatiske fluorglycosidhydrater, lægemidler, der omfatter disse forbindelser, og deres anvendelse
MX2012006634A (es) 2009-12-16 2012-06-21 Novo Nordisk As Derivados de peptidos tipo glucagon 1 de doble acilato.
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
IN2012DN06437A (da) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
SG185604A1 (en) * 2010-05-17 2012-12-28 Zhejiang Beta Pharma Inc Novel glucagon like peptide analogs, composition, and method of use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX347703B (es) 2011-06-22 2017-05-09 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1.
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN102827270A (zh) * 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 一种聚乙二醇化艾塞那肽衍生物及其用途
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
MX2015016564A (es) 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
CA2916311A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
AU2014359894B2 (en) 2013-12-06 2020-09-17 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2016083499A1 (en) 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
JP6691125B2 (ja) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
BR112017023145A2 (pt) 2015-06-04 2018-07-10 Antriabio Inc Método para produzir um conjugado de proteína- peg
CN106699870A (zh) * 2016-12-14 2017-05-24 江苏师范大学 长效非洲爪蟾胰高血糖素样肽‑1（glp‑1）类似物及其应用
WO2019106193A1 (en) 2017-12-01 2019-06-06 University Of Copenhagen Peptide hormone with one or more o-glycans
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
CN114478744A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效glp-1拮抗剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6495659B2 (en) 1999-12-22 2002-12-17 Shearwater Corporation Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
KR100847615B1 (ko) * 2000-06-16 2008-07-21 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
CA2468700A1 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
PL1605897T3 (pl) * 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
BRPI0411112A (pt) * 2003-06-12 2006-07-18 Lilly Co Eli proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
PL1641823T3 (pl) * 2003-06-12 2012-02-29 Lilly Co Eli Białka fuzyjne analogu GLP-1
CN1586625A (zh) * 2004-07-21 2005-03-02 上海第二医科大学附属瑞金医院 用于肿瘤显像和治疗的联合物及其制备方法

Also Published As

Publication number Publication date
ME02786B (me) 2011-10-31
JP2008540565A (ja) 2008-11-20
SI1881850T1 (sl) 2011-01-31
PT1881850E (pt) 2010-11-26
HRP20100543T1 (hr) 2010-11-30
UA90896C2 (en) 2010-06-10
EA012442B1 (ru) 2009-10-30
ES2350852T3 (es) 2011-01-27
CA2608311A1 (en) 2006-11-23
BRPI0609676A2 (pt) 2011-10-18
EP1881850A1 (en) 2008-01-30
JP2013079256A (ja) 2013-05-02
NO20076415L (no) 2007-12-12
EP1881850B1 (en) 2010-09-29
MX2007014052A (es) 2008-02-05
CN101166545A (zh) 2008-04-23
DE602006017202D1 (de) 2010-11-11
US20090215981A1 (en) 2009-08-27
WO2006124529A1 (en) 2006-11-23
EA200702487A1 (ru) 2008-04-28
JP5225074B2 (ja) 2013-07-03
IL186772A0 (en) 2008-02-09
AU2006247734A1 (en) 2006-11-23
RS51637B (en) 2011-10-31
CY1110853T1 (el) 2012-05-23
ATE482724T1 (de) 2010-10-15
CA2608311C (en) 2012-11-27
KR101011081B1 (ko) 2011-01-25
CN101166545B (zh) 2011-06-15
KR20080025361A (ko) 2008-03-20
US8183340B2 (en) 2012-05-22
AU2006247734B2 (en) 2011-06-23
PL1881850T3 (pl) 2011-03-31

Similar Documents

Publication Publication Date Title
ATE482724T1 (de) Pegylierte glp-1-verbindungen
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
WO2005091944A3 (en) Glycol linked fgf-21 compounds
CY1109269T1 (el) Συνθεσεις πρωτεϊνων συντηξεως αναλογων glp-1
MXPA05013565A (es) Proteinas de fusion analogas al glp-1.
DE602005016917D1 (de) Fgf-21-fusionsproteine
DK1196444T3 (da) Exendin-4-konjugater og deres medicinske anvendelighed
ATE509951T1 (de) Humanes interferon-beta-mutein
MX2007007174A (es) Derivados de cicloalquilamina.
EP1845105A4 (en) MODIFIED EXENDINES AND CORRESPONDING USES
UA85559C2 (en) Aminobenzophenone compounds
DK1727817T3 (da) Azabicyclooctan-3-onderivativer og anvendelse heraf
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
DE602006014530D1 (de) Pharmazeutisch aktive diazepane
ATE532510T1 (de) Aminosäure-phenoxy-ether, ihre herstellung und verwendungen
WO2006073771A3 (en) Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2005092362A3 (de) Pharmazeutisches kombinationspräparat enthaltend ein therapeutisches protein
DE502006006241D1 (de) Verwendung von amino substituierten benzimidazolen
ATE378415T1 (de) In cis regulierte konditionelle genvektoren
UA6163U (en) Anthelmintic drug "anhelmint"
ITRM20050522A1 (it) Proteine omeopatiche per la cura del diabete mellito di tipo 1 0 2 insulinotrattato.